News Results for GlaxoSmithKline (GSK)

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1645p (from 1620p). Story provided by StockMarketWire.com Broker Forecasts...

Oil prices and stocks fell amid an apparent escalation in the US-China trade war. After China announced tariffs on US goods and president Trump threatened retaliation on Twitter. The FTSE 100 was...

As investors awaited to hear a speech from the US Federal Reserve chair Jerome Powell the FTSE 100 was stronger, gaining 0.8% to 7,185.34. US futures pointed to a slightly higher open on Wall...

UK stocks opened higher on Friday after Peppa Pig owner Entertainment One soared on a takeover bid, and investors awaited a speech from Fed Chair Jerome Powell that could shed more light on the...

GlaxoSmithKline said a clinical study of its blood cancer treatment had met its primary goal. 'The two-arm study met its primary objective and demonstrated a clinically meaningful overall...

UK share markets plunged farther and faster in late afternoon trade to close firmly in the red as a slow start to US trading failed to lift ongoing worries over US interest rate cuts following the...

UK share markets continue their decline at midday on Thursday as uncertainty over the outlook for US interest rate cuts following the release of minutes from the Federal Reserve's last policy...

UK stocks are falling on Thursday as the market digested the Wednesday's Federal Reserve July meeting minutes, which provided little clarity for future direction. At 08:58, the benchmark FTSE 100...

ViiV Healthcare, a GlaxoSmithKline-Pfizer joint venture, said its injectable HIV treatment had met its primary goal in a clinical trial, reducing the number of treatments needed every year,...

GlaxoSmithKline said it had submitted an application for a drug that treats renal anaemia in patients with chronic kidney disease to the Japanese health regulator. 'Around 3.5 million patients in...

JP Morgan Cazenove today initiates coverage of GlaxoSmithKline PLC (LON:GSK) with a neutral investment rating and price target of 1700p. Story provided by StockMarketWire.com Broker Forecasts...

GlaxoSmithKline said it had completed its transaction with Pfizer to combine their consumer healthcare businesses into a joint venture. 'Now the deal has closed, our focus will be on completing...

GlaxoSmithKline's ViiV Healthcare joint venture with Pfizer said it had submitted a marketing authorisation application to the European Medicines Agency for its once-monthly injectable HIV-1...

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1620p (from 1575p). Story provided by StockMarketWire.com Broker Forecasts...

Pharmaceutical company GlaxoSmithKline upgraded its annual earnings guidance after sales rose 7% in the second quarter. The company also announced that John Symonds, the current deputy chairman of...

UBS today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1610p (from 1630p). Story provided by StockMarketWire.com Broker Forecasts data...

Despite a weak US open, with the S&P 500 modestly lower in early trades, the FTSE 100 enjoyed decent gains on Monday. The positive performance coming as sterling took a tumble amid continuing...

The FTSE 100 was up by midday, advancing 0.2% to 7,520.77 after slipping into the red earlier. Investors apparently focused on the positive elements of China's latest growth figures, announced...

UK stocks opened slightly higher on Monday after the release of a mixed set of Chinese data that showed economic growth slowing but better-than-expected industrial output and retail sales. At...

GlaxoSmithKline said a clinical trial of its ovarian cancer treatment had met its primary goal. Niraparib, GSK's ovarian cancer drug demonstrated 'significant improvement' in progression free...

Emma Walmsley, Chief Executive Officer, has re-invested 19 shares in the company on the 11th July 2019 at a price of 1650.60p. The Director now holds 674,491 shares. NOTE: Re Share Reward Plan...

Emma Walmsley, Chief Executive Officer, bought 8 shares in the company on the 9th July 2019 at a price of 1636.22p. The Director now holds 674,472 shares. NOTE: Partnership Shares: Also awarded 8...

GlaxoSmithKline's ViiV Healthcare joint venture with Pfizer said its two-drug HIV treatment regime had met its primary goals after demonstrating a similar level of efficacy in controlling HIV-1 as...

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1575p (from 1550p). Story provided by StockMarketWire.com Broker Forecasts...

GlaxoSmithKline said its ViiV Healthcare joint venture with Pfizer received marketing authorisation from the European Commission for its two-drug treatment for HIV. Marketing Authorisation for the...

The FTSE 100 endured a downbeat end to the week, falling more than 0.5% as the pharmaceutical sector came under some pressure. GlaxoSmithKline fell 1.3%, AstraZeneca was down 2% and Reckitt...

Morgan Stanley today initiates coverage of GlaxoSmithKline PLC (LON:GSK) with a underweight investment rating and price target of 1520p. Story provided by StockMarketWire.com Broker Forecasts...

Kepler Cheuvreux today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1540p (from 1440p). Story provided by StockMarketWire.com Broker...

A 1.1% rise in the FTSE 100 helped to put investors in a better mood at the end of the trading week. Helping the blue chip index was a 1.4% rise in the oil price which lifted shares in Royal Dutch...

The FTSE 100 traded 0.9% higher at 7,322 at 12.30pm on Friday, tracking gains in Asia and elsewhere in Europe, as investors warmed to the prospect of interest rate cuts to stave off global growth...

GlaxoSmithKline said that the Federal Drug Administration had approved two new methods for administering the company's asthma treatment. This approval would give healthcare professionals and...

GlaxoSmithKline said that the European Medicines Agency's Committee had issued a 'positive' opinion recommending two new methods for administering the company's asthma treatment. The agency...

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1550p (from 1520p). Story provided by StockMarketWire.com Broker Forecasts...

Bryan Garnier today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1660p (from 1710p). Story provided by StockMarketWire.com Broker Forecasts...

Sir Philip Hampton, Chairman, bought 2,790 shares in the company on the 1st May 2019 at a price of 1568.00p. The Director now holds 54,241 shares representing 0.00% of the shares in issue. Story...

Manvinder Banga, Non Executive Director, bought 458 shares in the company on the 1st May 2019 at a price of 1568.00p. The Director now holds 3,861 shares representing 0.00% of the shares in issue....

Dr Vivienne Cox, Non Executive Director, bought 339 shares in the company on the 1st May 2019 at a price of 1568.00p. The Director now holds 3,971 shares representing 0.00% of the shares in issue....

Urs Rohner, Non Executive Director, bought 458 shares in the company on the 1st May 2019 at a price of 1568.00p. The Director now holds 8,522 shares representing 0.00% of the shares in issue....

Pharmaceuticals giant GlaxoSmithKline posted a rise in first-quarter earnings and reaffirmed its annual guidance following strong sales of its shingles vaccine and HIV treatments. Earnings per...

GlaxoSmithKline said its ViiV Healthcare joint venture had submitted a new drug application to the FDA seeking approval for two-drug HIV treatment regime. The monthly and injectable regimen...

Simon Dingemans, Financial Director, has re-invested 4,619 shares in the company on the 12th April 2019 at a price of 1565.60p. The Director now holds 99,648 shares representing 0.00% of the shares...

Emma Walmsley, Chief Executive Officer, has re-invested 1,856 shares in the company on the 15th April 2019 at a price of 1550.09p. The Director now holds 682,108 shares. Story provided by...

Global equities fell into the red after US President Donald Trump threatened tariffs on $11bn of European goods. At close, the FTSE 100 was 0.3% lower at 7,425. Elsewhere, European equities also...

The FTSE 100 was up a handful of points by midday at 7,455.71 with investors weighing the latest Brexit developments, as Theresa May headed to Berlin, as well as rising tensions between the EU and...

GlaxoSmithKline said its ViiV Healthcare joint venture with Pfizer received regulatory approval for its two-drug treatment for HIV from the US Food and Drug Administration. Dovato, a two-drug...

Weak economic data from the US and China weighed on global equities, as they added to concerns over global growth. The FTSE 100 fell 0.7% to 7,104. US jobs data was weaker than expected after...

Weak Chinese export data dialed up fears on global growth and sent the FTSE 100 sharply into reverse with US jobs numbers to come this afternoon. By midday the index of leading UK shares was down...

Shore Capital today downgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to hold (from buy). Story provided by StockMarketWire.com Broker Forecasts data provided by...

GlaxoSmithKline said Friday its ViiV Healthcare joint venture with Pfizer had recorded positive results from two clinical trials of an injectable two-drug regime for the treatment of HIV. The...

Britain's Serious Fraud Office said it had dropped investigations into individuals at GlaxoSmithKline and Rolls-Royce. 'After an extensive and careful examination I have concluded that there is...

UBS today downgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to neutral (from buy) and cut its price target to 1650p (from 1700p). Story provided by StockMarketWire.com Broker...

Simon Dingemans, Financial Director, exercised 68,442 shares in the company on the 18th February 2019 at a price of 0.00p. The Director now holds 982,153 shares. Story provided by...

Simon Dingemans, Financial Director, sold post-exercise 32,218 shares in the company on the 18th February 2019 at a price of 1517.60p. The Director now holds 949,935 shares. NOTE: Sold to meet tax...

Emma Walmsley, Chief Executive Officer, exercised 51,830 shares in the company on the 18th February 2019 at a price of 0.00p. The Director now holds 704,632 shares. Story provided by...

Emma Walmsley, Chief Executive Officer, sold post-exercise 24,398 shares in the company on the 18th February 2019 at a price of 1575.60p. The Director now holds 680,234 shares. NOTE: Sold to meet...

Emma Walmsley, Chief Executive Officer, sold 66,159 shares in the company on the 15th February 2019 at a price of 1584.62p. The Director now holds 652,802 shares. NOTE: Sold to meet tax...

HSBC today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1860p (from 1820p). Story provided by StockMarketWire.com Broker Forecasts data...

Sir Philip Hampton, Chairman, bought 2,926 shares in the company on the 6th February 2019 at a price of 1495.00p. The Director now holds 51,451 shares representing 0.00% of the shares in issue....

Manvinder Banga, Non Executive Director, bought 481 shares in the company on the 6th February 2019 at a price of 1495.00p. The Director now holds 3,403 shares representing 0.00% of the shares in...

Dr Vivienne Cox, Non Executive Director, bought 355 shares in the company on the 6th February 2019 at a price of 1495.00p. The Director now holds 3,632 shares representing 0.00% of the shares in...

Dr Vivienne Cox, Non Executive Director, bought 355 shares in the company on the 6th February 2019 at a price of 1495.00p. The Director now holds 3,632 shares representing 0.00% of the shares in...

GlaxoSmithKline posted a 36% rise in pre-tax profit, underpinned higher sales of its shingles vaccine and respiratory disease treatments, but warned of lower earnings in 2019. Pre-tax profit for...

GlaxoSmithKline agreed to offer Merck up to €3.7bn (£3.2bn) to form a partnership to develop an immonutherapy for the treatment of cancer. The deal involved GSK making an upfront payment to Merck...

GlaxoSmithKline said it had completed the acquisition of oncology-focused Tesaro for around $5.1bn (£4.0bn). The transaction was first announced in December. At 2:28pm: (LON:GSK) GlaxoSmithKline...

There was little sign of progress on Brexit after Theresa May lost a key vote on her withdrawal bill last week. The FTSE 100 was broadly unmoved at 6,970 although this was better than a sea of red...

The FTSE 100 was up 0.15% to 6,978.52 by midday amid volatile trading in sterling as Theresa May prepares to go back to MPs with a plan B on Brexit. Other European markets were in the red after...

UK stocks started the week in positive territory Monday as continued Brexit uncertainty weighed on the pound, helping exporters, and investors held out hope that China and the US would strike a...

GlaxoSmithKline said chairman Philip Hampton would stand down following the pharmaceutical company's decision to separate out its consumer health business. A search for Hampton's successor was...

Emma Walmsley, Chief Executive Officer, has re-invested 1,536 shares in the company on the 11th January 2019 at a price of 1528.75p. The Director now holds 526,361 shares. Story provided by...

Simon Dingemans, Financial Director, has re-invested 1,051 shares in the company on the 11th January 2019 at a price of 1528.75p. The Director now holds 694,100 shares. Story provided by...

Emma Walmsley, Chief Executive Officer, has re-invested 1,588 shares in the company on the 11th January 2019 at a price of 1536.00p. The Director now holds 524,825 shares. Story provided by...

Simon Dingemans, Financial Director, has re-invested 1,457 shares in the company on the 11th January 2019 at a price of 1536.00p. The Director now holds 691,055 shares. Story provided by...

Simon Dingemans, Financial Director, has re-invested 1,994 shares in the company on the 11th January 2019 at a price of 1536.00p. The Director now holds 693,049 shares. Story provided by...

GlaxoSmithKline said it had extended its $5.1bn takeover bid for Tesaro until Thursday to accommodate related regulatory procedures in Europe. The bid was originally scheduled to expire late on...

Emma Walmsley, Chief Executive Officer, has re-invested 18 shares in the company on the 10th January 2019 at a price of 1524.40p. The Director now holds 523,229 shares. Story provided by...

Simon Dingemans, Financial Director, has re-invested 24 shares in the company on the 10th January 2019 at a price of 1524.40p. The Director now holds 689,590 shares. Story provided by...

A bounce back in commodity prices lifted the mining sector, helping the FTSE 100 rise 0.9% to 6,765. Among the biggest risers were Evraz, Glencore and Rio Tinto with gains of at least 2.1% each....

The FTSE 100 was gathering strength by midday, up 0.9% to 6,762.04, investors hoping today's expected rate hike from the US Federal Reserve will be accompanied by guidance for a slower pace of...

UK stocks opened stronger on Wednesday after merger news boosted healthcare stocks and investors braced for a Fed rates decision due later in the day. At 0850, the benchmark FTSE 100 index was up...

GlaxoSmithKline reached agreement with Pfizer on Wednesday to combine their consumer health businesses into a new joint venture. Under the agreement, GSK would have a majority controlling equity...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1750p (from 1725p). Story provided by StockMarketWire.com Broker...

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1520p (from 1525p). Story provided by StockMarketWire.com Broker Forecasts...

Barclays Capital today downgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to equal weight (from overweight). Story provided by StockMarketWire.com Broker Forecasts data provided by...

The FTSE 100 continued to enjoy gains following a temporary truce in the US-China trade war over the weekend, which could boost growth and support demand for resources. Saudi Arabia and Russia...

Pharmaceutical giant GlaxoSmithKline said it had agreed to acquire US oncology-focused company Tesaro for around $5.1bn (£4.0bn). GSK said the deal would significantly strengthen its...

HSBC today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 2000p (from 2030p). Story provided by StockMarketWire.com Broker Forecasts data...

UK stocks rose slightly on Monday led by heavyweight defensive sectors such as healthcare and tobacco along with a few banks. Just before midday, the benchmark FTSE 100 index was up 23 points or...

Sir Philip Hampton, Chairman, bought 2,867 shares in the company on the 31st October 2018 at a price of 1526.00p. The Director now holds 49,525 shares representing 0.00% of the shares in issue....

Manvinder Banga, Non Executive Director, bought 471 shares in the company on the 31st October 2018 at a price of 1526.00p. The Director now holds 2,922 shares representing 0.00% of the shares in...

Dr Vivienne Cox, Non Executive Director, bought 348 shares in the company on the 31st October 2018 at a price of 1526.00p. The Director now holds 3,277 shares representing 0.00% of the shares in...

Dr Vivienne Cox, Non Executive Director, bought 348 shares in the company on the 31st October 2018 at a price of 1526.00p. The Director now holds 3,277 shares representing 0.00% of the shares in...

GlaxoSmithKline and Pfizer's ViiV Healthcare released positive results of a study testing the effectiveness of fostemsavir in heavily treatment-experienced HIV patients. Fostemsavir, in...

GlaxoSmithKline slightly upgraded its annual guidance after bumper sales of its shingles vaccine Shingrix helped it boost third-quarter operating profit by 2%. Operating profit for the three...

GlaxoSmithKline said its ViiV Healthcare joint venture with Pfizer had reported positive results from a study of a long-acting and injectable two-drug regime for the treatment of HIV. The...

GlaxoSmithKline said its ViiV Healthcare joint venture with Pfizer had presented positive study results for an HIV treatment regime at a conference in Glasgow. ViiV presented three-year results...

Simon Dingemans, Financial Director, has re-invested 2,083 shares in the company on the 12th October 2018 at a price of 1451.60p. The Director now holds 689,550 shares. Story provided by...

Emma Walmsley, Chief Executive Officer, bought 1,588 shares in the company on the 12th October 2018 at a price of 1458.79p. The Director now holds 521,536 shares. Story provided by...

Simon Dingemans, Financial Director, has re-invested 1,086 shares in the company on the 11th October 2018 at a price of 1458.79p. The Director now holds 685,949 shares. Story provided by...

GlaxoSmithKline said European regulators had issued a positive opinion of a treatment for chronic obstructive pulmonary disease. The European Medicines Agency's Committee for Medicinal Products...